Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma

Celgene plans to submit sNDA by end of 2019 Celgene plans additional studies with the AIDS Malignancy Consortium in U.S. and sub-Saharan Africa Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® (pomalidomide) for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi sarcoma who have previously received systemic chemotherapy, as well as patients with HIV‐negative Kaposi’s...

GT Biopharma shows elimination of HIV infected cells using tri-specific killer engagers (TriKEs) in preclinical trial

In preclinical testing at the Masonic Cancer Center a the University of Minnesota, a series of Bi and Tri Specific killer-engager (BiKE and TriKE) constructs were tested as a means to direct natural killer cells against an HIV infected target, and were found to destroy HIV cells. BiKE and TriKE based therapies have been studied at the Masonic Cancer Center for many years, with an emphasis on treating cancer and leukemia. Researchers at MCC...

St. Jude publishes results of Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency (‘bubble boy disease’)

St. Jude Children's research hospital has published the results of a lentiviral gene therapy for XSCID, showing early signs of robust improvements in the immune system of 8 patients, ranging from months old to 2 years old, in a pilot study of a gene transfer therapy. XSCID, AKA X-Linked Severe Combined Immunodeficiency is the result of a mutated chromosome, which can be either be inherited or naturally occurring. The mutation results in an immune...